Conference - Boston, MA, United States
As the bridge between genotype and phenotype, the field of epigenetic research has enormous potential to progress diagnosis and therapy in oncology and the wider disease spectrum.
The enormous pan-disease potential of epigenetic based drugs is now beginning to encourage floods of investment as excellent basic research is being translated into clinical utility. In 2009, sales of the 4 approved epigenetic drugs reached $519m. Now, such is the pace of development that Global Industry Analysts are expecting market value to grow to $18.2bn by 2015.
Realizing such immense potential will require thought leaders to address very specific challenges. Calls to action are being made to identify and validate new targets and confront attendant issues in assay development and the availability of quality reagents. Industry and academia also agree that more must be done to productively integrate recent advances in the basic and clinical sciences.
With strong representation and candid discussion guaranteed from senior level figures at Pfizer, GSK, Celgene, Constellation Pharmaceuticals and Epizyme, the 3rd World Epigenetics Summit will address these concerns directly and deliver commercially directed insight into the most pressing technical and strategic issues at hand.
This year’s World Epigenetics Summit will look to build on the successes of our two previous events and thereby provide a platform to help speed the development of better, more effective epigenetic drugs.
(Photo courtesy of http://www.epigenetics-summit.com/)
24th - 26th July 2012
W Boston, 100 Stuart Street
Boston, MA 02116, USA
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.